Current and Long-Term Liabilities (Details) (USD $)	3 Months Ended			12 Months Ended			12 Months Ended				12 Months Ended
	Dec. 31, 2012	Jun. 30, 2012	Dec. 31, 2013	Dec. 31, 2012 Takeda	Dec. 31, 2010 Takeda	Dec. 31, 2013 Takeda	Dec. 31, 2013 Takeda upfront payments and milestone payments	Dec. 31, 2012 Takeda upfront payments and milestone payments	Dec. 31, 2013 Takeda products shipped but not yet sold	Dec. 31, 2012 Other short-term deferred revenues	Dec. 31, 2008 3SBio	Dec. 31, 2013 3SBio	Dec. 31, 2012 3SBio
Accrued Expenses
Clinical, manufacturing and regulatory consulting fees and expenses	$ 7,737,000		$ 7,834,000
Salaries, bonuses, and other compensation	5,236,000		5,419,000
Commercial rebates, fees and returns	3,448,000		4,839,000
Professional, license, and other fees and expenses	1,719,000		1,932,000
Commercial consulting fees and expenses	815,000		1,301,000
Short-term contingent consideration			941,000
Restructuring expense	1,383,000
Total accrued expenses	20,338,000		22,266,000
Deferred Revenues
Total short-term deferred revenues	9,104,000		8,226,000	8,854,000		8,226,000				250,000
Total long-term deferred revenues	50,350,000		44,534,000	49,350,000		43,534,000						1,000,000	1,000,000
Upfront payment received											1,000,000
Amortization period for recognizing nonsubstantive milestone payments					10 years
Milestone payments received under agreement related to commercial launches				18,000,000
Milestone revenue recognized	5,000,000	15,000,000
Deferred revenue recognized							7,900,000	11,100,000
Deferred revenues							$ 49,300,000		$ 2,400,000